Previous 10 | Next 10 |
2024-03-19 06:53:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avenue Therapeutics (NASDAQ: ATXI ) just reported results for the fourth quarter of 2023. Avenue Therapeutics reported earnings per share of 56 cents. This was above the a...
2024-03-18 16:46:33 ET More on Avenue Therapeutics Avenue Therapeutics granted extension for Nasdaq compliance Avenue Therapeutics signs warrant exercise transactions for $5.0M in proceeds Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical ...
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy Society (AES) and American Society for Experimental Neurotherapeuti...
2024-03-15 08:53:49 ET More on Avenue Therapeutics Avenue Therapeutics signs warrant exercise transactions for $5.0M in proceeds Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earnings data for Avenue Therapeutics Financial information ...
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Na...
2024-01-24 16:22:17 ET More on Avenue Therapeutics Avenue Therapeutics signs warrant exercise transactions for $5.0M in proceeds Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earning...
NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 17-18, 2024. The presentation schedule is su...
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
2024-01-05 09:33:29 ET More on Avenue Therapeutics Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 Avenue Therapeutics stock plummets on pricing of 16.6M units at $0.3006 in public offering Seeking Alpha’s Quant Rating on Avenue Therapeutics Histo...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...